BCL-X expression in multiple myeloma: Possible indicator of chemoresistance

Cancer Research

Volumn 58, Issue 2, 1998, Pages 256-262

  Tu, Yiping ^a   Renner, Steven ^a   Xu, Feng Hao ^a   Fleishman, Alex ^a   Taylor, Jeremy ^a   Weisz, Jeffrey ^b   Vescio, Robert ^a   Rettig, Matthew ^a   Berenson, James ^a   Krajewski, Stanislaw ^c   Reed, John C ^c   Lichtenstein, Alan ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c BURNHAM INSTITUTE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTO ONCOGENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; BONE MARROW CELLS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, PLASMACYTIC; MULTIPLE MYELOMA; MYELOMA PROTEINS; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0031984216     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Drewinko, B., Alexanian, R., Boyer, H., Barlogie, B., and Rubinow, S. The growth fraction of human myeloma cells. Blood, 57: 333-339, 1981.
2. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., and Berenson, J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol., 162: 248-256, 1995.
3. Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., and Epstein, J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 84: 3063-3070, 1994.
4. Kawano, M., Mihara, K., Huang, N., Tsujimoto, T., and Kuramoto, A. Differentiation of early plasma cells on bone marrow stromal calls requires IL-6 for escaping from apoptosis. Blood, 85: 487-494, 1995.
5. Gardner, A., Xu, F., Tu, Y., Michl, P., Prager, D., and Lichtenstein, A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Proc. Am. Soc. Hematol. Blood, 88: 295a, 1996.
6. Mariano, M., Moretti, L., Donelli, A., Grantini, M., Montagnani, G., di Prisco, A. U., Torelli, G., Torelli, U., and Narni, F. BCL-2 gene expression in hematopoietic cell differentiation. Blood, 80: 768-775, 1992.
7. Pettersson, M., Jernberg-Wiklund, H., Larsson, L. G., Sundstrom, C., Givol, I., Tsujimoto, Y., and Nilsson, K. Expression of the BCL-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood, 79, 495-502, 1992.
8. Tu, Y., Xu, F-H., Liu, J., Vescio, R., Berenson, J., Fady, C., and Lichtenstein, A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide and hydrogen peroxide. Blood, 88: 1805-1812, 1996.
9. Schwarze, M. M. K., and Hawley, R. G. Prevention of myeloma cell apoptosis by ectopic BCL expression or interleukin-6 mediated up-regulation of BCL-X-L. Cancer Res., 55: 2262-2269, 1995.
10. Boise, L. H., Gonzales-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G., and Thompson, C. B. BCL-X, a BCL-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597-604, 1993.
11. Lotem, J., and Sachs, L. Regulation of BCL-2, BCL-X and BAX in the control of apoptosis by hematopoioetic cytokines and dexamethasone. Cell Growth Differ., 6: 647-654, 1995.
12. Krajewski, S., Krajewski, M., Shabaik, A., Wang, H-G., Irie, S., Fong, L., and Reed, J. C. Immunohistochemical analysis of in vivo patterns of BCL-X expression. Cancer Res., 54: 5501-5509, 1994.
13. Gauthier, E. R., Piche, L., Lemieux, G., and Lemieux, R. Role of BCL-XL in the control of apoptosis in murine myeloma cells. Cancer Res., 56: 1451-1456, 1996.
14. Lichtenstein, A., Gera, J., Andrews, J., Berenson, J., and Ware, C. Inhibitors of ADP-ribose polymerase decrease the resistance of HER2/neu-expressing cancer cells to the cytotoxic effects of tumor necrosis factor. J. Immunol., 146: 2052-2059, 1991.
15. Dalton, W. S., Durie, B. G. M., Alberts, D. S., Gerlach, J. H., and Cress, A. E. Characterization of a new drug-resistant myeloma cell line that expresses P-glycoprotein. Cancer Res., 46: 5125-5130, 1986.
16. Xerri, L., Parc, P., Brousset, P., Schlaifer, D., Hassoun, J., Reed, J. C., Krajewski, S., and Birnbaum, D. Predominant expression of the long isoform of BCL-X in human lymphomas. Br. J. Hematol., 92, 900-907, 1996.
17. Sclaifer, D., March, M., Krajewski, S., Laurent, G., Pris, J., Delsol, G., Reed, J. C., and Brousset, P. High expression of the BCL-X gene in Reed-Sternberg cells of Hodgkin's disease. Blood, 85: 2671-2677, 1995.
18. Krajewski, M., Moss, S. F., Krajewski, S., Song, K., Holt, P. R., and Reed, J. C. Elevated expression of BCL-X and reduced BAK in primary colorectal carcinoma. Cancer Res., 56: 2422-2429, 1996.
19. Krajewski, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S., and Reed, J. C. Immunohistochemical analysis of BCL-2, BAX, BCL-X and MCL-1 expression in prostate cancers. Am. J. Pathol., 148: 1567-1575, 1996.
20. Krajewski, M., Fenoglio-Preiser, C. M., Krajewski, S., Song, K., MacDonald, J. S., Stemmerman, G., and Reed, J. C. Immunohistochemical analysis of BCL-2 family proteins in adenocarcinoma of the stomach. Am. J. Pathol., 149: 1449-1458, 1996.
21. Krajewski, S., Krajewski, M., Ehrmann, J., Sikorska, M., Lach, B., Chatten, J., and Reed, J. C. Immunohistochemical analysis of BCL-2, BCL-X, MCL-1 and BAX in tumors of central and peripheral nervous system origin. Am. J. Pathol., in press, 1997.
22. Sato, T., Hanada, M., Bodrug, S., Irie, S., Iwama, N., Boise, L. H., Thompson, C. B., Golemis, E., Wong, L., Wang, H. G., and Reed, J. C. Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. USA, 91: 9238-9245, 1994.
23. Chao, D. T., Linette, G. P., Boise, L. H., White, L. S., Thompson, C. B., and Korsmayer, S. J. BCL-X-L and BCL-2 repress a common pathway of cell death. J. Exp. Med., 182: 821-834, 1995.
24. Minn, A. J., Boise, L. H., and Thompson, C. B. BCL-X-S antagonizes the protective effects of BCL-X-L. J. Biol. Chem., 271: 6306-6312, 1996.
25. Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S-L., Ng, S-C., and Fesik, S. W. X-ray and NMR structure of human BCL-X-L, an inhibitor of programmed cell death. Nature (Lond.), 381: 335-340, 1996.
26. Grillot, D. A. M., Merino, R., Pena, J. C., Fanslow, W. C., Finkelman, F. D., Thompson, C. B., and Nunez, G. BCL-X exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J. Exp. Med., 183: 381-393, 1996.
27. Bataille, R., Jourdan, H., Zhang, X-G., and Klein, B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J. Clin. Invest., 84: 2008-2015, 1989.
28. Levy, Y., Tsapis, A., and Brouet, J-C. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J. Clin. Invest., 88, 696-704, 1991.
29. Salmon, S., Grogan, T. M., Miller, T., Scheper, R., and Dalton, W. S. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma and breast cancer by P-glycoprotein staining. J. Natl. Cancer Inst. (Bethesda), 81: 696-704, 1989.
30. Epstein, J., Xiao, H., and Oba, B. K. P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood, 74: 913-920, 1989.
31. Salmon, S., Dalton, W. S., Grogan, T. M., Plezia, P., Lehnen, M., Roe, D. J., and Miller, T. P. Multidrug-resistant myeloma: laboratory and clinical effects of verapimil as a chemosensitizer. Blood, 78: 44-53, 1991.
32. Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G. M., Taylor, C. W., Miller, T. P., and Salmon, S. E. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapimil to chemotherapy. J. Clin. Oncol., 7: 415-423, 1989.
33. Sonneveld, P., Schoester, M., and de Leeuw, K. Clinical modulation of multidrug resistance in multiple myeloma. Effect of cyclosporine on resistant tumor cells. J. Clin. Oncol., 12: 1584-1595, 1994.
34. Sonneveld, P., Durie, B. G. M., Lokhorst, H. M., Marie, J. P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, B., and Nooter, K. Modulation of multidrug resistant multiple myeloma by cyclosporine. Lancet, 340: 255-259, 1992.
35. Grogan, T. M., Spier, C. M., Salmon, S. E., Matzner, M., Rybski, J., Weinstein, R. S., Scheper, R. J., and Dalton, W. S. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood, 81: 490-497, 1993.
36. Minn, A. J., Rudin, C. M., Boise, L. H., and Thompson, C. B. Expression of BCL-X-L can confer a multidrug resistance phenotype. Blood, 86: 1903-1909, 1995.
37. Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Nunez, G., and Castle, V. P. BCL-X-L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55: 2576-2584, 1995.
38. Geyp, M., Ireland, C. M., and Pittman, S. M. Resistance to apoptotic cell death in a drug resistant T cell leukemia cell line. Leukemia (Baltimore), 10: 447-455, 1996.
39. Frankfurt, O. S., Secklinger, D., and Sugarbaker, E. V. Pleiotropic drug resistance and survival advantage in leukemic cells with diminished apoptotic response. Int. J. Cancer, 59: 217-224, 1994.
40. Segal-Bendirdjian, E., and Jacquemin-Sablon, A. Cisplatin resistance in a murine leukemic cell line is associated with a defective apoptotic response. Exp. Cell Res., 218: 201-210, 1995.
41. Datta, R., Manome, Y., Taneja, N., Boise, L., Wechselbaum, R., Thompson, C. B., Slapak, C. A., and Kufe, D. Overexpression of BCL-X-L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ., 6: 363-370, 1995.
42. Han, Z., Chaterjee, D., Early, J., Pantazis, P., Hendrickson, E. A., and Wyche, J. H. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from BCL-2 to BCL-X-L. Cancer Res., 56: 1621-1628, 1996.
43. Landowski, T. H., Gleason-Guzman, M. C., and Dalton, W. S. Selection for drug resistance results in resistance in fas-mediated apoptosis. Blood 89: 1854-1863, 1997.
44. Wattel, E., Vanrumbeke, M., Abina, M. A., Cambier, N., Preudhomme, C., Haddada, H., and Fenaux, P. Differential efficacy of adenoviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies. Leukemia (Baltimore), 10: 171-180, 1996.
45. Salmon, S. E., Soehnlen, B., Dalton,. W. S., Meltzer, P., and Scuderi, P. Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. Blood, 74: 1723-1730, 1989.